Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda

Journal of the International AIDS Society

Volumn 18, Issue , 2015, Pages

  Ying, Roger ^a   Sharma, Monisha ^a   Heffron, Renee ^a   Celum, Connie L ^a   Baeten, Jared M ^a   Katabira, Elly ^b   Bulya, Nulu ^b   Barnabas, Ruanne V ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c USA   (United States)

Author keywords

ART; Cost effectiveness analysis; Mathematical modeling; PrEP; Serodiscordant couples

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISABILITY ADJUSTED LIFE YEAR; GOVERNMENT; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SEXUAL BEHAVIOR; UGANDA; VIRUS TRANSMISSION; ECONOMICS; FEMALE; HIV INFECTIONS; MALE; SEXUALITY;

ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MALE; PRE-EXPOSURE PROPHYLAXIS; SEXUAL PARTNERS; UGANDA;

EID: 84938217939     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.18.4.20013     Document Type: Article

References (48)

1. UNAIDS/WHO. Global report: UNAIDS report on the global AIDS epidemic, 2013. Geneva: Joint United Nations Programme on HIV/AIDS; 2013.
2. UNAIDS. Fast-Track: ending the AIDS epidemic by 2030. Geneva: Joint United Nations Programme on HIV/AIDS; 2014.
3. Bor J, Herbst AJ, Newell ML, Bärnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013;339:961-5.
4. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339:966-71.
5. Katz IT, Essien T, Marinda ET, Gray GE, Bangsberg DR, Martinson NA, et al. Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS. 2011;25:2177-81.
6. Mujugira A, Celum C, Thomas KK, Farquhar C, Mugo N, Katabira E, et al. Delay of antiretroviral therapy initiation is common in East African HIV-infected individuals in serodiscordant partnerships. J Acquir Immune Defic Syndr. 2014; 66:436-42.
7. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99.
8. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329:1168-74.
9. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083-90.
10. Mugo NR. Notes from the field: implementing PrEP in resource constrained settings. Boston, MA: CROI; 2014.
11. Baeten J. Near elimination of HIV transmission in a demonstration project of PrEP and ART; 2015 February 23-26; Seattle, WA: Conference on Retroviruses and Opportunistic Infections; 2015.
12. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-22.
13. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Preexposure prophylaxis for HIV in Women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections; 2013 Mar 3-6; Atlanta, GA.
14. Ying R, Celum C, Baeten J, Murnane P, Hong T, Krows M, et al. Pre-exposure prophylaxis for young women with concomitant partner testing can costeffectively reduce HIV incidence in KwaZulu-Natal, South Africa; 2014 April 1-4; Vancouver, Canada: International HIV Treatment as Prevention Workshop; 2014.
15. Anderson SJ, Cherutich P, Kilonzo N, Cremin I, Fecht D, Kimanga D, et al. Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need: a modelling study. Lancet. 2014;384: 249-56.
16. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.
17. Celum C, Baeten JM, Hughes JP, Barnabas R, Liu A, Van Rooyen H, et al. Integrated strategies for combination HIV prevention: principles and examples for men who have sex with men in the Americas and heterosexual African populations. J Acquir Immune Defic Syndr. 2013;63(Suppl 2):S213-20.
18. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin I , et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011;8:e1001123.
19. Verguet S, Stalcup M, Walsh JA. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa? Sex Transm Infect. 2013;89:628-34.
20. Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012;54:1504-13.
21. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 2013;10: e1001401.
22. Heffron R, Celum C, Mugo N, Katabira E, Bukusi E, Asiimwe S, et al. High initiation and adherence among high risk African HIV discordant couples in a demonstration project of PrEP and ART for HIV prevention. Cape Town: HIV Research for Prevention; 2014.
23. Kahle EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba E, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr. 2013;62:339-47.
24. Heffron R, Ngure K, Semiyaga NB, Odoyo J, Tindimwebwa E, Morton J, et al. Sustained PrEP use among high-risk African HIV serodiscordant couples in a PrEP demonstration project, 2015 February 23-26; Seattle: Conference on Retroviruses and Opportunistic Infections; 2015.
25. Clinton Health Access Initiative. Facility-based unit costing for antiretroviral treatment in five sub-Saharan African countries. Boston: The Clinton Health Access Initiative; 2011.
26. UNAIDS. Costing guidelines for HIV prevention strategies. Geneva: UNAIDS; 2000.
27. Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
28. Drummond MF. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press; 1997.
29. The Employment Act. Edited by Ministry of Gender L, and Social Development. Kampala, Uganda; 2006.
30. Africa Health Workforce Observatory. Human resources for health: country profile, Uganda. Geneva: WHO; 2009.
31. Clinton Health Access Initiative. Antiretroviral (ARV) ceiling price list. Boston: Clinton Health Access Initiative (CHAI); 2013.
32. Lee HH, Dineva MA, Chua YL, Ritchie AV, Ushiro-Lumb I, Wisniewski CA. Simple amplification-based assay: a nucleic acid-based point-of-care platform for HIV-1 testing. J Infect Dis. 2010;201(Suppl 1):S65-72.
33. Gish RG, Gutierrez JA, Navarro-Cazarez N, Giang K, Adler D, Tran B, et al. A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation. J Viral Hepat. 2014;21:905-8.
34. Bedelu M, Ford N, Hilderbrand K, Reuter H. Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis. 2007;196(Suppl 3):S464-8.
35. Barnabas R, Ying R, van Rooyen H, Murnane P, Hughes J, Baeten J, et al. Use of HIV viral-load suppression to estimate the effect of community-wide home-based HIV counselling and testing and linkage to antiretroviral therapy on HIV incidence in South Africa: a mathematical modelling analysis. Lancet. 2013;382:S6.
36. Barnabas RV, Van Rooyen H, Baeten J, Tumwesigye E, Phakathi Z, Tumwebaze H, et al. High testing uptake and linkages to HIV treatment through home-based HIV counseling and testing and facilitated referral in Kabwohe, Uganda and KwaZulu-Natal (KZN), South Africa. In: Treatment as prevention. Vancouver, Canada; 2012.
37. National AIDS and STI Control Programme (NASCOP), Kenya. Kenya AIDS Indicator Survey 2012: Final Report. Nairobi: NASCOP; 2014.
38. Meyer-Rath G, Brennan AT, Fox MP, Modisenyane T, Tshabangu N, Mohapi L, et al. Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa. J Acquir Immune Defic Syndr. 2013;62:322-8.
39. International Monetary Fund.World economic outlook database.Washington, D.C.: International Monetary Fund; 2012.
40. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
41. Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2014;14:1055-64.
42. World Health Organization. Guidance on Pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. Geneva: World Health Organization; 2012.
43. Callaghan M, Ford N, Schneider H. A systematic review of task-shifting for HIV treatment and care in Africa. Hum Resour Health. 2010;8:8.
44. Campion EW. Treating millions for HIV -The adherence clubs of Khayelitsha. N Engl J Med. 2015;372:301-3.
45. Larson BA, Bii M, Henly-Thomas S, McCoy K, Sawe F, Shaffer D, et al. ART treatment costs and retention in care in Kenya: a cohort study in three rural outpatient clinics. J Int AIDS Soc. 2013;16:18026, doi: http://dx.doi.org/10.7448/IAS.16.1.18026
46. Menzies NA, Berruti AA, Berzon R, Filler S, Ferris R, Ellerbrock TV, et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS. 2011;25:1753-60.
47. Bill & Melinda Gates Foundation. Oral PrEP in South Africa. Bottom-up cost model. Seattle, USA: Bill and Melinda Gates Foundation; 2011.
48. Pines HA, Gorbach PM, Weiss RE, Shoptaw S, Landovitz RJ, Javanbakht M, et al. Sexual risk trajectories among MSM in the United States: implications for pre-exposure prophylaxis delivery. J Acquir Immune Defic Syndr. 2014;65: 579-86.